Therapeutic Vaccines


A consultation to help determine the intersection between therapeutic and preventive vaccines.

The therapeutic vaccine field has seen a revival in the recent years, largely associated with the cure agenda. The Enterprise, together with AVAC, the Treatment Action Group, and the Bill & Melinda Gates Foundation, organized a . to discuss the state of the field and to provide strategic recommendations for future developments. As part of that meeting, one session specifically focused on common points of interest and between the preventive and therapeutic vaccine areas. The consultation also updated the therapeutic vaccine community on progress in preventive vaccine research and look for ways to collaborate moving forward. 

The meeting took place on 19-20 September, 2013 in Bethesda North Marriot Hotel and Conference Center in Bethesda, Maryland.

Agenda and Participants

The consultation focused on the following questions: 

  • What are the required immunologic responses for therapeutic vaccines?
  • What can we learn from therapeutic vaccine studies in NHPs?
  • What can we learn from human clinical trials of therapeutic vaccines?
  • What can be learned from testing vaccine candidates as preventive and therapeutic vaccines?
  • What is the role for therapeutic vaccines in the Cure scientific agenda?

Organizing Committee

  • Jose Esparza, the Bill & Melinda Gates Foundation
  • Kevin Fisher, AVAC: Global Advocacy for HIV Prevention
  • Richard Jefferys, the Treatment Action Group (TAG)
  • Magda Moutaftsi, the Bill & Melinda Gates Foundation
  • Yegor Voronin, Global HIV Vaccine Enterprise

Objectives for the Enterprise

  • Update therapeutic vaccines community on scientific progress in preventive vaccines
  • Share the wealth of immunological data from preventive vaccines with the therapeutic vaccine field
  • Identify potential intersections between therapeutic and preventive research and areas for follow up

Strategic Directions for Therapeutic Vaccines webinar

On 18 November 2013 we held a webinar to discuss the preliminary recommendations coming out of the meeting in Bethesda. The webinar included a presentation by Richard Jefferys (TAG), and a Q&A with Christian Brander, Jose Esparza, Genoveffa Franchini, Harriet Robinson, and Janet Siliciano.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account